Lipotest meal - Lipotest is

The LIPOTEST meal is

The Lipotest meal is a diagnostic meal used to diagnose the abnormal postprandial lipaemia (Fat Tolerance Test)

The abnormal postprandial lipaemia is connected with increased cardiovascular risk which Fat Tolerance Test diagnoses early

Contains exactly the indicated by the studies composition which is required to perform the Fat Tolerance Test (specific amount of saturated fat, carbohydrate and protein)

Ιt is available in powder form, which when blended with water becomes a tasty mousse (chocolate flavor), that can be consumed easily by the patient in order to perform the Fat Tolerance Test

It is recognized by the EOF as "food for specialized diagnostic triglycerides determination"

Ιt is the only diagnostic meal worldwide in commercial form, which can be used for the Fat Tolerance Test which when it is abnormal it predicts the increased vascular risk


More specific:
The LIPOTEST meal is a diagnostic meal with special medical purpose, characterized by EOF as "Food for specialized diagnostic determination of postprandial triglycerides"(EOF REFERENCE NUMBER 13664/21-2-12, 75198/23-10-12).

It is the appropriate diagnostic meal for those subjects who undergo the Fat Tolerance Test.

Fat Tolerance Test is the measurement of postprandial triglyceride levels after the consumption of a standardized meal. It can be compared to oral glucose tolerance test, but it is used for evaluation of the metabolism of blood lipids. It provides early information of any abnormal postprandial lipid metabolism.

In order to perform the Fat Tolerance Test - in the literature it is referred as Fat Tolerance Test (FTT) – the determination of plasma triglyceride level takes place four hours after the individual's consumption of a standardized fatty meal. If the value is over 220 mg/dl the Fat Tolerance Test is positive.

As it is known, after the consumption of such meals, the plasma lipid levels are increased. Triglycerides and Chylomicrons are mainly increased, and are rapidly metabolized.

However, when there is defective postprandial metabolism, they remain in plasma in high levels for a long time.

The prolonged elevated levels of postprandial triglycerides have the following pathophysiologic consequences:
• They promote the formation of small, dense and more atherogenic LDL by loading them with triglycerides.
• They promote the formation of small dense HDL by loading them with triglycerides. These HDL are not as functional as normal HDL.
• They increase plasma triglycerides remnants, which have atherogenic action as well.

lipotest meal These changes promote atherosclerosis.

The Fat Tolerant test elucidates this pathogenesis of atherosclerosis; if the body is able to metabolize the postprandial fat effectively.

When the Fat Tolerance Test is positive, it means that the body does not metabolize effectively the dietary fat, so there is a high risk for development of atherosclerotic plaques and consequently vascular events (myocardial infarction or stroke).

However, if the problem is early diagnosed and the necessary treatment begins, then the risk can be reduced.

After a month of treatment (medicine and / or dietary) the Fat Tolerance Test is repeated and must be negative (for monitoring response to therapy). If it remains positive the treatment should be modified (the treatment should reduce postprandial triglycerides in normal values).

In the Triglyceride's section, there is description of the mechanism of the elevated triglycerides, related literature and international guidelines of the Fat Tolerance Test and postprandial triglyceride determination.

The composition of the Lipotest – meal:
The LIPOTEST meal contains saturated fat, sugars and milk protein.

In details, it consists of:
Hydrogenated vegetable fat, corn syrup solids, milk protein, sugar, emulsifiers: lactic and acetic acid esters of mono- and diglycerides of fatty acids, cocoa (20-22% fat), skimmed cocoa (10-12% fat), Flavorings.

It may contain traces of cereals which contain gluten.

VIDEO: Postprandial Lipemia and Cardiovascular Risk Video >>watch the video